Lung Cancer 2006, 52:155–163.PubMedCrossRef 20. Belani CP, Waterhouse H, Ghazal H, et al.: Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer BAY 1895344 price (NSCLC). J Clin Oncol 2010,28(15s):abstr 7506. 21. Perol M, Chouaid C, Milleron J, et al.: Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy
in advanced NSCLC: IFCT-GFPC 0502 phase III study. J Clin Oncol 2010,28(15s):abstr 7507. 22. Belani CP, Barstis J, Perry MC, La Rocca RV, Nattam SR, Rinaldi D, Clark R, Mills GM: Multicenter, randomized trial for stage IIIB or IV non small cell lung cancer using weekly paclitaxel or observation. J Clin Oncol 2003, 21:2933–2939.PubMedCrossRef 23. Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumours to their spontaneous mutation rate. Cancer Treat Rep 1979, 63:1727–17233.PubMed 24. Coate LE, Shepherd FA: Maintenance therapy in advanced
non small cell lung cancer. JTO 2010,5(5):723–734. 25. Westeel V, Quoix E, Moro Sibilot D, Mercier M, Breton JL, Debieuvre D, Richard selleck kinase inhibitor P, Haller MA, Milleron B, Herman D, Level MC, Puyraveau M, Depierre
A: Randomized study of maintenance vinorelbine in responders with advanced MLN0128 cell line non-small cell lung cancer. J Natl Cancer Inst 2005, 97:499–506.PubMedCrossRef 26. Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL, Chen R, Kazmierski MH, Treat J, Obasaju CK, Marciniak M, Gill J, Schiller JH: Phase III study of immediate versus delayed docetaxel after front line therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer. J Clin Oncol 2009, 27:591–8.PubMedCrossRef 27. Ciuleanu T, Brodowicz T, Zielinski C Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira J, Yang SH, Madhavan J, Sugarman KP, MM-102 datasheet Peterson P, John WJ, Krejcy K, Belani CP: Maintenance pemetrexed plus best supportive care vesus placebo plus best supportive care for non-small cell lung cancer: a randomized double-blind, phase III study. Lancet 2009, 374:1432–4.PubMedCrossRef 28. Scagliotti GV, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA: The differential efficacy of pemetrexed according to NSCLC histology, a review of two phase III studies. Oncologist 2009, 14:253–63.PubMedCrossRef 29.